ID

13060

Descrição

Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00083577

Link

https://clinicaltrials.gov/show/NCT00083577

Palavras-chave

  1. 13/01/2016 13/01/2016 -
Titular dos direitos

CC BY-NC 3.0

Transferido a

13 de janeiro de 2016

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Multiple Myeloma NCT00083577

Eligibility Multiple Myeloma NCT00083577

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
all patients must have a confirmed diagnosis of previously treated, active multiple myeloma
Descrição

multiple myeloma

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0026764
myeloma protein should be evident from which to evaluate response
Descrição

myeloma protein

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0027015
must be 18 years of age or older. women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
Descrição

age, contraception

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0700589
patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug
Descrição

informed consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
patients must have a total white blood cell count of 2,000 k/microliters. patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma
Descrição

white blood cell count

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0023508
patients must have adequate liver function as demonstrated by a direct bilirubin of < or = 2.0 mg/dl.
Descrição

liver function

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1278039
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients must not have an active infection requiring parenteral antibiotics
Descrição

active infection

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0009450
no other concurrent therapy for myeloma is permitted while on thalidomide
Descrição

concurrent therapy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0039736

Similar models

Eligibility Multiple Myeloma NCT00083577

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
multiple myeloma
Item
all patients must have a confirmed diagnosis of previously treated, active multiple myeloma
boolean
C0026764 (UMLS CUI [1])
myeloma protein
Item
myeloma protein should be evident from which to evaluate response
boolean
C0027015 (UMLS CUI [1])
age, contraception
Item
must be 18 years of age or older. women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
boolean
C0001779 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
informed consent
Item
patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug
boolean
C0021430 (UMLS CUI [1])
white blood cell count
Item
patients must have a total white blood cell count of 2,000 k/microliters. patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma
boolean
C0023508 (UMLS CUI [1])
liver function
Item
patients must have adequate liver function as demonstrated by a direct bilirubin of < or = 2.0 mg/dl.
boolean
C1278039 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
active infection
Item
patients must not have an active infection requiring parenteral antibiotics
boolean
C0009450 (UMLS CUI [1])
concurrent therapy
Item
no other concurrent therapy for myeloma is permitted while on thalidomide
boolean
C0039736 (UMLS CUI [1])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial